Common Contracts
5 similar Employment Agreement contracts by Osmotica Pharmaceuticals PLC, Osmotica Pharmaceuticals LTD
EMPLOYMENT AGREEMENTEmployment Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated May 2, 2016, is entered into by and between Vertical/Trigen Opco, LLC (the “Company”), which is a wholly-owned subsidiary of Vertical/Trigen Holdings, LLC (“Holdings”), and Tina deVries (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated December 16, 2013, is entered into by and between Vertical/Trigen Opco, LLC (the “Company”), which is a wholly-owned subsidiary of Vertical/Trigen Holdings, LLC (“Holdings”), and James Schaub (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated May 2, 2016, is entered into by and between Vertical/Trigen Opco, LLC (the “Company”), which is a wholly-owned subsidiary of Vertical/Trigen Holdings, LLC (“Holdings”), and Tina deVries (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 20th, 2018 • Osmotica Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated May 2, 2016, is entered into by and between Vertical/Trigen Opco, LLC (the “Company”), which is a wholly-owned subsidiary of Vertical/Trigen Holdings, LLC (“Holdings”), and Tina deVries (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 20th, 2018 • Osmotica Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated December 16, 2013, is entered into by and between Vertical/Trigen Opco, LLC (the “Company”), which is a wholly-owned subsidiary of Vertical/Trigen Holdings, LLC (“Holdings”), and James Schaub (the “Executive”).
